

Catalytic Enantioselective aza-Reformatsky Reaction with Seven-Membered Cyclic Imines Dibenzo[*b,f*][1,4]oxazepines

 Lode De Munck,[‡] Verena Sukowski, [‡] Carlos Vila,^{*a} M. Carmen Muñoz^b and José R. Pedro^{*a}

 Received 00th January 20xx,
 Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

A catalytic enantioselective aza-Reformatsky reaction is reported with cyclic dibenzo[*b,f*][1,4]oxazepines and ethyl iodoacetate leading to the synthesis of chiral ethyl 2-(10,11-dihydrodibenzo[*b,f*][1,4]oxazepin-11-yl)acetate derivatives with excellent yields and high enantioselectivities (up to 98% yield and 97:3 er) using a readily available diaryl prolinol L4 as chiral ligand and Me₂Zn as zinc source in the presence of air atmosphere. Furthermore, different transformations were carried out with the corresponding chiral β-amino esters, preserving in all cases the optical purity.

Introduction

The dibenzo[*b,f*][1,4]oxazepine scaffold is an important pharmacophore and, over the last years, has attracted much attention in pharmaceutical industry and medicinal chemistry due to the fact that this structure is present in numerous compounds with a broad range of biological activities.¹ In this context, several 11-substituted-10,11-dihydrodibenzo[*b,f*][1,4]oxazepine derivatives have been described possessing different physiological activities (Figure 1). For example, Sintamil² and its analogue compound **A** have antidepressant activity, compound **B** is a progesterone receptor agonist,³ while compound **C** presents antihistaminic activity.⁴ Despite the importance of this pharmacophore, catalytic enantioselective methodologies to prepare optically pure 11-substituted-10,11-dihydrodibenzo[*b,f*][1,4]oxazepine derivatives are scarce. So far, two organocatalyzed Mannich reactions,⁵ an asymmetric alkynylation⁶ and iridium catalyzed asymmetric hydrogenations of the corresponding seven-membered ketimines⁷ have been reported. Consequently, the development of other catalytic enantioselective reactions to prepare these chiral seven-membered nitrogen heterocyclic compounds is an important aim in organic synthesis.

On the other hand, chiral β-amino esters are a significant class of building blocks in synthetic chemistry, which have been used for the synthesis of optically pure β-amino alcohols or β-amino acids. Chiral β-amino acids⁸ are key structural elements of peptides and peptidomimetics,⁹ and are precursors of β-lactams.¹⁰ Catalytic enantioselective Reformatsky^{11,12} reaction using imines as electrophiles provides a suitable methodology for the synthesis of chiral β-amino esters. However, the catalytic asymmetric Reformatsky reaction with imines is hardly studied, in contrast to corresponding reaction using aldehydes¹³ or ketones.¹⁴ Only two examples of enantioselective aza-Reformatsky reaction have been described in the literature by Cozzi¹⁵ and our group.¹⁶ To the best of our knowledge, seven-membered cyclic imines has not been used as electrophiles in this reaction. We envisioned that the cyclic imines dibenzo[*b,f*][1,4]oxazepines would be interesting electrophiles for the barely studied asymmetric aza-Reformatsky reaction. Herein, we present our results using these seven-membered cyclic imines as substrates and ethyl iodoacetate as reagent, in the presence of a readily available diaryl prolinol as chiral ligand and Me₂Zn as zinc source under air atmosphere, providing chiral β-amino esters with high yields and enantioselectivities.




Figure 1 Derivatives of cyclic amines containing dibenzo[*b,f*][1,4]oxazepines motif.

Results and discussion

Our initial studies were focused on the addition of ethyl iodoacetate (**2**) to dibenzo[*b,f*][1,4]oxazepine **1a** in the presence of Me₂Zn and various chiral amino alcohols under air atmosphere. As shown in Table 1, when 20 mol% of quinine (**L1**)

^a Departament de Química Orgànica, Facultat de Química, Universitat de València, Dr. Moliner 50, 46100 Burjassot, València (Spain).

^b Departament de Física Aplicada, Universitat Politècnica de València, Camino de Vera s/n, 46022 València (Spain).

[†] Footnotes relating to the title and/or authors should appear here.


Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

DOI: 10.1039/x0xx00000x

[‡] These authors contributed equally.

was used in diethyl ether, 45% yield was obtained, providing the compound ethyl 2-(10,11-dihydrodibenzo[*b,f*][1,4]oxazepin-11-yl)acetate **3a** with a poor enantiomeric ratio (43:57). After, we tested *N*-methyl ephedrine **L2**, used by Cozzi,¹⁵ and the corresponding β -amino ester **3a** was obtained with moderate yield and higher enantiomeric ratio (34.5:65.5). However, this er was still unsatisfactory (entry 2, Table 1). After, we decided to investigate the use of several commercially available chiral diaryl prolinols **L3-L6** (entries 3-6, Table 1). We observed higher enantioselectivities with this kind of ligands, obtaining the highest er (73:27) when (*S*)-bis(3,5-dimethylphenyl)(pyrrolidin-2-yl)methanol **L4** was used as ligand. Therefore we continued the optimization process with **L4**, testing different solvents (entries 7-15, Table 1). With ethereal solvents (*i*Pr₂O, THF or MTBE) similar levels of enantioselectivities were obtained for compound **3a**.

Table 1 Optimization of the reaction conditions.^a




L1
L2
L3, Ar = Ph
L4, Ar = 3,5-Me₂-C₆H₃
L5, Ar = 3,5-(CF₃)₂-C₆H₃
L6, Ar = 2-naphthyl

Entry	Ligand (x mol%)	Solvent	T (°C)	Yield (%) ^b	er ^c
1	L1 (20 mol%)	Et ₂ O	rt	45	43:57
2	L2 (20 mol%)	Et ₂ O	rt	42	34.5:65.5
3	L3 (20 mol%)	Et ₂ O	rt	57	67:33
4	L4 (20 mol%)	Et ₂ O	rt	42	73:27
5	L5 (20 mol%)	Et ₂ O	rt	71	69.5:30.5
6	L6 (20 mol%)	Et ₂ O	rt	36	71.5:28.5
7	L4 (20 mol%)	<i>i</i> Pr ₂ O	rt	54	76.5:23.5
8	L4 (20 mol%)	MTBE	rt	47	77.5:22.5
9	L4 (20 mol%)	THF	rt	63	74.5:25.5
10	L4 (20 mol%)	Toluene	rt	33	68.5:31.5
11	L4 (20 mol%)	CH ₂ Cl ₂	rt	44	76.5:23.5
12	L4 (20 mol%)	CICH ₂ CH ₂ Cl	rt	51	78:22
13	L4 (20 mol%)	CHCl ₃	rt	29	73:27
14	L4 (20 mol%)	CH ₃ CN	rt	53	74:26
15	L4 (20 mol%)	AcOEt	rt	63	79.5:20.5
16	L4 (20 mol%)	AcOEt	0	22	94:6
17 ^d	L4 (20 mol%)	AcOEt	0	78	91:9
18 ^d	L4 (20 mol%)	AcOEt	-10	40	94:6
19 ^{d,e}	L4 (20 mol%)	AcOEt	0	75	84:16
20 ^{d,f}	L4 (20 mol%)	AcOEt	0	71	87:13
21 ^{d,g}	L4 (20 mol%)	AcOEt	0	97	93.5:6.5
22 ^{d,g}	L4 (10 mol%)	AcOEt	0	92	93:7

^a **1a** (0.1 mmol), **2** (0.2 mmol), Me₂Zn (7 eq.) and ligand (x mol%) in 3 mL of solvent. ^b Isolated yield after column chromatography. ^c Determined by HPLC using chiral stationary phase. ^d 3 equivalents of **2** were used. ^e 7 equivalents of Et₂Zn were used. ^f 1.5 mL of EtOAc was used. ^g 6 mL of EtOAc was used.

Chlorinated solvents such as dichloromethane or dichloroethane lead to similar enantiomeric ratios, while chloroform gave lower yield and enantioselectivity. Finally, when EtOAc was used as solvent the corresponding chiral β -amino ester was obtained with good yield (63%) and the best enantioselectivity (79.5:20.5 er, entry 15).

Therefore, EtOAc was chosen for further optimization. Lowering the reaction temperature to 0 °C, improve the enantioselectivity (94:6 er), but the yield was low (22%). By increasing the number of the equivalents of ethyl iodoacetate, we could improve the yield (78%), keeping the enantioselectivity high (91:9 er) for the aza-Reformatsky reaction. However, when we lowered the temperature to -10 °C, the enantioselectivity increased but the yield was much lower (40%). Consequently, we decided to carry out the reaction at 0°C. Furthermore, Et₂Zn was used as the zinc source in the model reaction (entry 19), obtaining good yield (75%) but a lower enantioselectivity (84:16 er). Working at lower concentration, (entry 21) had an improvement both in yield and enantioselectivity (97% yield and 93.5:6.5 er). A reduction of the catalyst load to 10 mol% had a slightly deleterious effect on the yield (92%) but not in the enantioselectivity of the reaction (93:7 er, entry 22).¹⁷



Scheme 1. Scope of the aza-Reformatsky reaction with dibenzo[*b,f*][1,4]oxazepines **1**: **1** (0.1 mmol), **2** (0.3 mmol), Me₂Zn (7 eq.) and **L4** (x mol%) in 6 mL of AcOEt. Isolated yields after column chromatography. Enantiomeric ratio were determined by HPLC using chiral stationary phase. ^a 10 mol% of **L4** was used. ^b 20 mol% of **L4** was used.

Under the optimized reaction conditions (entries 21 and 22, Table 1), a variety of substituted dibenzo[*b,f*][1,4]oxazepines were subjected to the aza-Reformatsky reaction (Scheme 1). A wide range of substituted cyclic imines **1**, with both electron-donating and electron-withdrawing substituents at different positions of the two aromatic rings, afforded the corresponding chiral β -amino esters **3a-3o** with high yields (up to 99%) and enantioselectivities (up to 97:3 er). For the cyclic imine **1k**, bearing two methoxy groups in the aromatic ring a lower enantioselectivity was obtained (89.5:10.5 er) probably due to the presence of the methoxy group next to the C=N electrophilic bond. However the yield was excellent (94% yield). Cyclic imines bearing a naphthyl ring (**1m-1o**) afforded the corresponding products with high enantiomeric ratio and excellent yields.¹⁸

The absolute configuration of the stereogenic center in compound **3o** was determined to be (*S*) on the basis of X-ray crystallographic analysis (Figure 2); the configuration of the rest of the products **3** was assigned on the assumption of a uniform mechanistic pathway.¹⁹





Figure 2 X-ray structure of compound **3o**.


With the above successful results, we further investigated the aza-Reformatsky reaction of dibenzo[*b,f*][1,4]thiazepine **4** with ethyl iodoacetate (Scheme 2). Dihydrodibenzothiazine is also an important and widely used scaffold in medicinal chemistry,²⁰ although its synthesis using catalytic asymmetric procedures are limited to the asymmetric hydrogenation of the corresponding seven-membered ketimines.²¹ When the cyclic imine **4** was used as a substrate, the corresponding β -amino ester **5** was obtained with excellent yield (95%) and high enantiomeric ratio (94.5: 5.5).



Scheme 2. Aza-Reformatsky reaction with dibenzo[*b,f*][1,4]thiazepine **4**: **4** (0.1 mmol), **2** (0.3 mmol), Me₂Zn (7 eq.) and **L4** (20 mol%) in 6 mL of AcOEt. Isolated yields after column chromatography. Enantiomeric ratio was determined by HPLC using chiral stationary phase.

To highlight the synthetic utility of this methodology, we have applied several chemical transformations for the synthesis of interesting chiral compounds bearing a dibenzo[*b,f*][1,4]oxazepine

scaffold (Scheme 3). The ester moiety of product **3a** provides a convenient site for further modification. For example, chiral β -amino acid **6** was prepared in 86% yield and without loss of optical purity by simple saponification of the ester moiety. Chiral amino alcohol **7**, was synthesized by reduction of the β -amino ester with LiAlH₄. Furthermore, the interesting 11-vinyl-10,11-dihydrodibenzo[*b,f*][1,4]oxazepine **8** was easily synthesized by a three step reaction sequence with an overall yield of 54% yield and maintaining the optical purity.²² Finally, a Suzuki cross-coupling reaction was performed using (4-methoxyphenyl)boronic acid and the chiral 10,11-dihydrodibenzo[*b,f*][1,4]oxazepine **3o**, obtaining the corresponding chiral product **9** in 83% yield and 95:5 er.



Scheme 3. Synthetic transformations: a) NaOH 1M in EtOH at 75 °C. b) LiAlH₄ in THF at 0 °C. c) *o*-nitrophenyl selenocyanate (2.4 eq.) and PBU₃ (2.5 eq.) in THF at rt. d) 5 eq. of H₂O₂ (50% aqueous solution) in THF at 0 °C, then rt. e) ArB(OH)₂ (2 eq.), K₃PO₄ (8 eq.) and PdCl₂(PPh₃)₂ (10 mol%) in DMF at 80 °C. Ar= *p*-MeOC₆H₄-.

Conclusions

In summary, we have developed a catalytic enantioselective aza-Reformatsky reaction with seven membered cyclic imines. In our methodology, dibenzo[*b,f*][1,4]oxazepines **1** and dibenzo[*b,f*][1,4]thiazepine **4** can be used as electrophiles obtaining chiral β -amino esters with high enantiomeric ratios. Our approach represents the first catalytic enantioselective aza-Reformatsky reaction with this class of cyclic imines. Moreover, several transformations have been made with the chiral β -amino esters obtained. Studies to further extend the scope of this reaction are currently underway in our laboratory.

Acknowledgements

Financial support from the MINECO (Gobierno de España; CTQ2013-47494-P) is gratefully acknowledged. L. M. thanks the Generalitat Valenciana for a predoctoral grant. C.V. thanks MINECO for a JdC contract.

Notes and references

- (a) J. M. Klunder, K. D. Hargrave, M. West, E. Cullen, K. Pal, M. L. Behnke, S. R. Kapadia, D. W. McNeil, J. C. Wu, G. C. Chow and J. Adams, *J. Med. Chem.*, 1992, **35**, 1887; (b) V. J. Merluzzi, K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup and J. L. Sullivan, *Science* 1990 **250**, 1411; (c) R. A. Smits, H. D. Lim, B. Stegink, R. A. Bakker, I. J. P. de Esch and R. Leurs, *J. Med. Chem.* 2006, **49**, 4512; (d) R. Li, P. S. Farmer, J. Wang, R. J. Boyd, T. S. Cameron, M. A. Quilliam, J. A. Walter and S. E. Howlett, *Drug Des. Discov.* 1995, **12**, 337; (e) W. E. Coyne and J. W. Cusic, *J. Med. Chem.* 1968, **11**, 1158; (f) E. A. Hallinan, T. J. Hagen, S. Tsymbalov, A. Stapelfeld and M. A.; Savage, *Bioorg. Med. Chem.* 2001, **9**, 1; (g) E. A. Hallinan, T. J. Hagen, S. Tsymbalov, R. K. Husa, A. C. Lee, A. Stapelfeld and M. A.; Savage, *J. Med. Chem.* 1996, **39**, 609; (h) W. J. Van der Burg, *Chem. Abstr.* 1974, **81**, 3986; (i) G. Walther, C. S. Schneider, K. H. Weber and A. Fuegner, *Chem. Abstr.* 1982, **96**, 6777; (j) F. G. Sulman, Y. Pfeifer and E. Superstine, *Arzneimittelforschung* 1981, **31**, 109.
- (a) *Progress in Medicinal Chemistry*, Elsevier, 1985, **22**, 246; (b) A. Hadou, A. Hamid, H. Mathouet, M.-F. Deïda and A. Daïch, *Heterocycles* 2008, **76**, 1017.
- P. P. M. A. Dols, B. J. B. Folmer, H. Hamersma, C. W. Kuil, H. Lucas, L. Ollero, J. B. M. Rewinkel and P. H. H. Hermkens, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 1461.
- G. Walther, H. Daniel, W. D. Bechtel and K. Brandt, *Arzneim. Forsch.* 1990, **40**, 440.
- (a) Y.-Q. Wang and Y.-Y. Ren, *Chinese J. Catal.* 2015, **36**, 93; (b) Y.-Y. Ren, Y.-Q. Wang, S. Liu and K. Pan, *ChemCatChem*. 2014, **6**, 2985.
- Y.-Y. Ren, Y.-Q. Wang and S. Liu, *J. Org. Chem.* 2014, **79**, 11759.
- (a) K. Gao, C.-Bi. Yu, Y.-G. Zhou and X. Zhang, *Chem. Commun.* 2011, **47**, 7845; (b) B. Balakrishna, A. Bauzá, A. Frontera and A. Vidal-Ferran, *Chem. Eur. J.* 2016, **22**, 10607.
- For reviews on asymmetric synthesis of β -amino acids, see: (a) J.-A. Ma, *Angew. Chem. Int. Ed.* 2003, **42**, 4290; (b) M. Liu and M. P. Sibi, *Tetrahedron* 2002, **58**, 7991; (c) G. Cardillo and C. Tomasini, *Chem. Soc. Rev.* 1996, **25**, 117; (d) B. Weiner, W. Szymanski, D. B. Janssen, A. J. Minnaard and B. L. Feringa, *Chem. Soc. Rev.* 2010, **39**, 1656.
- (a) G. Lelais and D. Seebach, *Biopolymers* 2004, **76**, 206; (b) D. Seebach, T. Kimmerlin, R. Sebesta, M. A. Campo and A. K. Beck, *Tetrahedron* 2004, **60**, 7455; (c) D. Seebach and J. Gardiner, *Acc. Chem. Res.* 2008, **41**, 1366.
- (a) *Chemistry and Biology of β -Lactam Antibiotics*, Vols. 1–3 (Eds.: R. B. Morin, M. Goldman), Academic Press, New York, 1982; (b) D. J. Hart and D.-C. Ha, *Chem. Rev.* 1989, **89**, 1447; (c) C. R. Pitts and T. Lectka, *Chem. Rev.* 2014, **114**, 7930.
- S. Reformatsky, *Ber. Dtsch. Chem. Ges.* 1887, **20**, 1210.
- (a) M. A. Fernández-Ibáñez, B. Maciá, D. A. Alonso and I. M. Pastor, *Eur. J. Org. Chem.* 2013, 7028; (b) P. G. Cozzi, *Pure Appl. Chem.* 2008, **80**, 891. For a recent review of diastereoselective Reformatsky-type reactions, see: (c) S. Choppin, L. Ferreiro-Medeiros, M. Barbarotto and F. Colobert, *Chem. Soc. Rev.* 2013, **42**, 937.
- (a) M. A. Fernández-Ibáñez, B. Maciá, A. J. Minnaard and B. L. Feringa, *Angew. Chem. Int. Ed.* 2008, **47**, 1317; (b) P. G. Cozzi, F. Benfatti, M. Guiteras Capdevila and A. Mignogna, *Chem. Commun.* 2008, 3317; (c) C. Wolf and M. Moskowicz, *J. Org. Chem.* 2011, **76**, 6372; (d) N. Lin, M.-M. Chen, R.-S. Luo, Y.-Q. Deng and G. Lu, *Tetrahedron: Asymmetry* 2010, **21**, 2816.
- (a) P. G. Cozzi, *Angew. Chem. Int. Ed.* 2006, **45**, 2951; (b) P. G. Cozzi, A. Mignogna and L. Zoli, *Synthesis* 2007, **17**, 2746; (c) M. A. Fernández-Ibáñez, B. Maciá, A. J. Minnaard and B. L. Feringa, *Chem. Commun.* 2008, 2571; (d) M. A. Fernández-Ibáñez, B. Maciá, A. J. Minnaard and B. L. Feringa, *Org. Lett.* 2008, **10**, 4041.
- P. G. Cozzi, *Adv. Synth. Catal.* 2006, **348**, 2075.
- L. De Munck, C. Vila, M. C. Muñoz and J. R. Pedro, *Chem. Eur. J.* 2016, **22**, 17590.
- The reaction was tested in a 0.5 mmol scale (100 mg) using 10 mol% of catalyst, obtaining the corresponding product **3a** in 95% yield and 93:7 er. However, when the reaction was scale up to 2 mmol (400 mg) using 10 mol% catalyst, the corresponding product **3a** was obtained with 89% yield and 85:15 er.
- The 11-methyldibenzo[b,f][1,4]oxazepine (a cyclic seven membered ketimine) was tested under the optimized reaction conditions, however poor conversion was observed (less than 10%) by ^1H NMR analysis of the crude reaction mixture.
- CCDC-1530500 (for **3o**) contains the supplementary crystallographic data. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- (a) Y. Liao, B. J. Venhuis, N. Rodenhuis, W. Timmerman, H. Wikström, E. Meier, G. D. Bartoszyk, H. Böttcher, C. A. Seyfried and S. Sundell, *J. Med. Chem.*, 1999, **42**, 2235; (b) J. M. Goldstein and L. A. Arvanitis, *CNS Drug Rev.* 1995, **1**, 50; (c) P. Catsoulacos *J. Heterocycl. Chem.* 1970 **7**, 409; (d) T. K. Jørgenson, R. Hohlweg, K. E. Andersen, U. B. Olsen, Z. Polivka, and K. Sindelar. *U.S. 6187770B1*, 2001; (e) R. C. Allen, P. A. Reitano and H. Urbach, *J. Med. Chem.*, 1978, **21**, 838.
- (a) R.-N. Guo, K. Gao, Z.-S. Ye, Y. Li and Y.-G. Zhou, *Pure Appl. Chem.* 2013, **85**, 843; (b) J. Wang, *Tetrahedron Lett.* 2013, **54**, 5956.
- (a) M. Arnó, B. García, J. R. Pedro and E. Seoane, *Tetrahedron* 1984, **40**, 5243; (b) M. Arnó, B. García, J. R. Pedro and E. Seoane, *Tetrahedron Lett.* 1983, **24**, 1741.